52969
document
A clinical trial of glutathione supplementation in autism spectrum disorders . BACKGROUND Recent evidence shows that subjects diagnosed with an autism spectrum disorder ( ASD ) have significantly lower levels of glutathione than typically developing children . The purpose of this study was to examine the use of two commonly used glutathione supplements in subjects diagnosed with an ASD to determine their efficacy in increasing blood glutathione levels in subjects diagnosed with an ASD . MATERIAL/METHODS The study was an eight-week , open-label trial using oral lipoceutical glutathione ( n=13 ) or transdermal glutathione ( n=13 ) in children , 3-13 years of age , with a diagnosis of an ASD . Subjects underwent pre- and post-treatment lab testing to evaluate plasma reduced glutathione , oxidized glutathione , cysteine , taurine , free and total sulfate , and whole-blood glutathione levels . RESULTS The oral treatment group showed significant increases in plasma reduced glutathione , but not whole-blood glutathione levels following supplementation . Both the oral and transdermal treatment groups showed significant increases in plasma sulfate , cysteine , and taurine following supplementation . CONCLUSIONS The results suggest that oral and transdermal glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites . Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms .
52970
Intervention_Pharmacological
oral lipoceutical glutathione
52971
Intervention_Pharmacological
transdermal glutathione
52972
Intervention_Pharmacological
glutathione
52973
Intervention_Pharmacological
glutathione
52974
Outcome_Physical
blood glutathione levels
52975
Outcome_Physical
plasma reduced glutathione , oxidized glutathione , cysteine , taurine , free and total sulfate , and whole-blood glutathione levels .
52976
Outcome_Physical
plasma reduced glutathione
52977
Outcome_Physical
whole-blood glutathione
52978
Outcome_Physical
plasma sulfate
52979
Outcome_Physical
cysteine
52980
Outcome_Physical
taurine
52981
Participant_Condition
autism spectrum disorders
52982
Participant_Condition
autism spectrum disorder ( ASD )
52983
Participant_Condition
ASD
52984
Participant_Condition
ASD
52985
Participant_Sample-size
n=13
52986
Participant_Sample-size
n=13
52987
Participant_Age
children
52988
Participant_Age
3-13
52989
Participant_Condition
ASD
52990
Participant_Condition
ASD